QIAGEN Gaithersburg, Inc.
Clinical trials sponsored by QIAGEN Gaithersburg, Inc., explained in plain language.
A subsidiary of QIAGEN, providing molecular diagnostics and sample preparation products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New test aims to speed up diagnosis of brain infections
Diagnosis OngoingThis study checks how well a new test, the QIAstat-Dx ME Panel Plus, can detect meningitis and encephalitis from spinal fluid samples. Researchers will compare the test results to standard methods using leftover samples from 1500 patients. The goal is to see if the test works acc…
Sponsor: QIAGEN Gaithersburg, Inc • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
New rapid test could speed up UTI diagnosis and antibiotic choice
Diagnosis OngoingThis study evaluates a new test called the QIAstat-Dx cUTI Plus AMR Panel, which aims to quickly detect bacteria and antibiotic resistance in urine samples from people with suspected complicated urinary tract infections (cUTI). Researchers will enroll 1500 participants of all age…
Sponsor: QIAGEN Gaithersburg, Inc • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC